Cleared Special

K020234 - A1CNOW FOR RX HOME USE

K020234 is an FDA 510(k) clearance for A1CNOW FOR RX HOME USE, manufactured by Metrika, Inc.. The device is a Class 2 Hematology device with product code LCP cleared through the Special 510(k) pathway after a 23-day FDA review.

K020234 · Metrika, Inc. · Hematology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Feb 2002
Decision
23d
Days
Class 2
Risk

K020234 is an FDA 510(k) clearance for the A1CNOW FOR RX HOME USE. Classified as Assay, Glycosylated Hemoglobin (product code LCP), Class II - Special Controls.

Submitted by Metrika, Inc. (Sunnyvale, US). The FDA issued a Cleared decision on February 15, 2002 after a review of 23 days - a notably fast clearance cycle.

This device falls under the Hematology FDA review panel, regulated under 21 CFR 864.7470 - the FDA hematology device framework. As a Special 510(k), this submission covers a manufacturer modification to an existing cleared device rather than a new device introduction.

Device pattern: Iterative device modification. Low regulatory complexity profile. This Special 510(k) clearance confirms that the manufacturer's modifications remained within the established regulatory envelope of the original cleared device.

FDA 510(k) Submission Details - K020234

510(k) Number K020234 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received January 23, 2002
Decision Date February 15, 2002
Days to Decision 23 days
Submission Type Special
Review Panel Hematology (HE)
Summary Statement
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
90d faster than avg
Panel avg: 113d · This submission: 23d
Pathway characteristics
Modification to existing cleared device.

LCP Device Classification - Class 2, Special Controls

Product Code LCP Assay, Glycosylated Hemoglobin
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 864.7470
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Hematology devices follow this clearance model.

Regulatory Peers - LCP Assay, Glycosylated Hemoglobin

All 247
Devices cleared under the same product code (LCP) and FDA review panel - the closest regulatory comparables to K020234.
RANDOX HAEMOGLOBIN A1C
K021897 · Randox Laboratories, Ltd. · Nov 2002
HEMOGLOBIN A1C CONTROL
K021484 · Canterbury Scientific , Ltd. · Jun 2002
POLYMEDCO HBA1C TEST
K020532 · Polymedco, Inc. · Apr 2002
A1CNOW FOR PROFESSIONAL USE
K020235 · Metrika, Inc. · Feb 2002
ACCU-BASE HEMOGLOBIN A1C SAMPLE COLLECTION KIT
K013465 · Diabetes Technologies, Inc. · Jan 2002
DIMENSION HAIC ASSAY, MODEL DF105
K011852 · Dade Behring, Inc. · Nov 2001
K020234 · A1CNOW FOR RX HOME USE
Download PDF Metrika, Inc.